Become A Featured Company

Microdosing: The Next Revolution in Psychedelics

Ryan Allway

April 22nd, 2021

App, Exclusive, Psychedelics, Top Story

The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders.

As states liberalize their psychedelics regulations, microdosing has become a popular trend that could offer a variety of mental health benefits. Research on microdosing remains in its infancy, but the combination of placebo-controlled studies and effective delivery systems could translate to a larger-scale trend over the coming years.

Let’s take a closer look at microdosing and how new technologies are making it easier to achieve a consistent result.

What is Microdosing?

Microdosing is the practice of consuming a very low, sub-hallucinogenic dose of a psychedelic substance, such as psilocybin or LSD. While scientific literature contains minimal research, there is plenty of anecdotal evidence to support the practice but the handful of high-quality studies that do exist paint a mixed picture of microdosing efficacy.

In 2018, the Imperial College of London conducted the first placebo-controlled study of microdosing practices. Participants received either a psychedelic or placebo and completed online surveys and cognitive tasks at regular intervals. The results showed improvements in both the psychedelic and placebo groups with no significant differences between them.

Other researchers believe that microdosing may still offer tangible benefits. Maastricht University researchers in the Netherlands conducted their own small-scale placebo-controlled study and found beneficial effects on mood and attention for some participants that couldn’t be explained by the placebo effect. They suggest that timing could be an important factor.

The same researchers from Maastricht University measured brain-derived neurotrophic factor (BNDF)—a protein that affects brain plasticity—and found an increase a few hours after microdosing psychedelics in blood tests. These findings suggest that there is some kind of physiological factor at play with microdosing practices.

 Ensuring the Right Dose

The varying effects of microdosing practices could be the results of varying metabolic rates and drug delivery mechanisms. For instance, capsule-based forms of microdosing involve swallowing a pill that is subject to second-pass metabolism in the liver. Sublingual delivery mechanisms, on the other hand, quickly move to the brain. 

Revive Therapeutics Ltd. (CSE: RVV) is building an intellectual property portfolio around psychedelic drug delivery. After acquiring Psilocin Pharma Corp., the company partnered with Complete Phytochemical Solutions and signed a sponsored research deal with the University of Wisconsin-Madison to develop new delivery methods for psychedelic substances.

The company’s dissolvable oral strips could be especially beneficial for microdosing, delivering between one and 20 milligrams of natural or synthetic psilocybin with rapid onset that bypasses liver metabolism. The company’s other products targeting both psychedelics and cannabinoids include lozenges, gels, creams and transdermal patches. 

While many companies undergo expensive clinical trials, the company’s innovative delivery systems could see a faster path to commercialization as California, Oregon and other states start to legalize psychedelics for personal use. These efforts could open the door to widespread microdosing practices to realize cognitive and other mental health benefits.

Looking Ahead

Investors interested in the psychedelics space may want to consider companies focused on microdosing practices since they could represent a nearer-term path to commercialization. Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) is a prime example with its dissolvable oral strip delivery system for psilocybin microdosing.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading